Progress in Understanding and Treating Idiopathic Pulmonary Fibrosis

Overview

Journal Annu Rev Med

Publisher Annual Reviews

Specialty General Medicine

Date 2019 Jan 30

PMID 30691371

Citations 57

Authors

Jonathan A Kropski

Timothy S Blackwell

Affiliations

Soon will be listed here.

Abstract

This is a time of substantial progress in the evaluation and care of patients with idiopathic pulmonary fibrosis (IPF). In addition to the approval and widespread availability of the first IPF-specific therapies, there have been improvements in imaging interpretation and lung biopsy methods to enable more expeditious and more accurate diagnosis. Recent advances in identifying genetic factors that underlie susceptibility to IPF and affect prognosis have raised the possibility of personalized therapeutic approaches in the future. Further, evolving work is elucidating novel mechanisms influencing epithelial, mesenchymal, and inflammatory cell responses during the injury-repair process, thus advancing understanding of disease pathogenesis. As analytic approaches mature, the field is now poised to harness the power of rapidly advancing "omics" technologies to further accelerate progress.

Citing Articles

Engineering Lipid Nanoparticles to Enhance Intracellular Delivery of Transforming Growth Factor-Beta siRNA (siTGF-β1) via Inhalation for Improving Pulmonary Fibrosis Post-Bleomycin Challenge.

Deng X, Yang Y, Gan L, Duan X, Wang X, Zhang J Pharmaceutics. 2025; 17(2).

PMID: 40006524 PMC: 11859093. DOI: 10.3390/pharmaceutics17020157.

Mean Platelet Volume-to-Platelet Count Ratio (MPR) in Acute Exacerbations of Idiopathic Pulmonary Fibrosis: A Novel Biomarker for ICU Mortality.

Ari M, Akinci Ozyurek B, Yildiz M, Ozdemir T, Hosgun D, Sahin Ozdemirel T Medicina (Kaunas). 2025; 61(2).

PMID: 40005361 PMC: 11857736. DOI: 10.3390/medicina61020244.

The Chemokine System as a Key Regulator of Pulmonary Fibrosis: Converging Pathways in Human Idiopathic Pulmonary Fibrosis (IPF) and the Bleomycin-Induced Lung Fibrosis Model in Mice.

Russo R, Ryffel B Cells. 2025; 13(24).

PMID: 39768150 PMC: 11674266. DOI: 10.3390/cells13242058.

Investigates the Role of PANoptosis in Idiopathic Pulmonary Fibrosis and Potential Therapeutic Targets.

Xiang Y, Huang G, Luo C, Jiang J, Zhang T, Zeng Q J Inflamm Res. 2024; 17:11605-11629.

PMID: 39737099 PMC: 11682943. DOI: 10.2147/JIR.S490457.

Exacerbation of pulmonary fibrosis following acute lung injury via activin-A production by recruited alveolar macrophages.

Pan T, Feng Y, Li Y, Yang Y, Zhou J, Song Y J Thorac Dis. 2024; 16(11):7709-7728.

PMID: 39678869 PMC: 11635239. DOI: 10.21037/jtd-24-680.

References

Stanley S, Gable D, Wagner C, Carlile T, Hanumanthu V, Podlevsky J . Loss-of-function mutations in the RNA biogenesis factor NAF1 predispose to pulmonary fibrosis-emphysema. Sci Transl Med. 2016; 8(351):351ra107. PMC: 5351811. DOI: 10.1126/scitranslmed.aaf7837. View

Alder J, Stanley S, Wagner C, Hamilton M, Hanumanthu V, Armanios M . Exome sequencing identifies mutant TINF2 in a family with pulmonary fibrosis. Chest. 2014; 147(5):1361-1368. PMC: 4420184. DOI: 10.1378/chest.14-1947. View

Kropski J, Blackwell T, Loyd J . The genetic basis of idiopathic pulmonary fibrosis. Eur Respir J. 2015; 45(6):1717-27. PMC: 4849867. DOI: 10.1183/09031936.00163814. View

Lawson W, Cheng D, Degryse A, Tanjore H, Polosukhin V, Xu X . Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs. Proc Natl Acad Sci U S A. 2011; 108(26):10562-7. PMC: 3127925. DOI: 10.1073/pnas.1107559108. View

Lynch D, Sverzellati N, Travis W, Brown K, Colby T, Galvin J . Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med. 2017; 6(2):138-153. DOI: 10.1016/S2213-2600(17)30433-2. View

Nathan S, Meyer K . IPF clinical trial design and endpoints. Curr Opin Pulm Med. 2014; 20(5):463-71. PMC: 4162322. DOI: 10.1097/MCP.0000000000000091. View

Young L, Gulleman P, Short C, Tanjore H, Sherrill T, Qi A . Epithelial-macrophage interactions determine pulmonary fibrosis susceptibility in Hermansky-Pudlak syndrome. JCI Insight. 2016; 1(17):e88947. PMC: 5070955. DOI: 10.1172/jci.insight.88947. View

Kropski J, Young L, Cogan J, Mitchell D, Lancaster L, Worrell J . Genetic Evaluation and Testing of Patients and Families with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2016; 195(11):1423-1428. PMC: 5470751. DOI: 10.1164/rccm.201609-1820PP. View

Nathan S, Albera C, Bradford W, Costabel U, Glaspole I, Glassberg M . Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2016; 5(1):33-41. DOI: 10.1016/S2213-2600(16)30326-5. View

10.

van Moorsel C, van Oosterhout M, Barlo N, de Jong P, van der Vis J, Ruven H . Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a dutch cohort. Am J Respir Crit Care Med. 2010; 182(11):1419-25. DOI: 10.1164/rccm.200906-0953OC. View

11.

Pankratz D, Choi Y, Imtiaz U, Fedorowicz G, Anderson J, Colby T . Usual Interstitial Pneumonia Can Be Detected in Transbronchial Biopsies Using Machine Learning. Ann Am Thorac Soc. 2017; 14(11):1646-1654. DOI: 10.1513/AnnalsATS.201612-947OC. View

12.

King Jr T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2083-92. DOI: 10.1056/NEJMoa1402582. View

13.

Korfei M, Ruppert C, Mahavadi P, Henneke I, Markart P, Koch M . Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008; 178(8):838-46. PMC: 2566794. DOI: 10.1164/rccm.200802-313OC. View

14.

Durheim M, Kim S, Gulack B, Burfeind W, Gaissert H, Kosinski A . Mortality and Respiratory Failure After Thoracoscopic Lung Biopsy for Interstitial Lung Disease. Ann Thorac Surg. 2017; 104(2):465-470. DOI: 10.1016/j.athoracsur.2017.02.013. View

15.

Xie T, Wang Y, Deng N, Huang G, Taghavifar F, Geng Y . Single-Cell Deconvolution of Fibroblast Heterogeneity in Mouse Pulmonary Fibrosis. Cell Rep. 2018; 22(13):3625-3640. PMC: 5908225. DOI: 10.1016/j.celrep.2018.03.010. View

16.

Richeldi L, Kreuter M, Selman M, Crestani B, Kirsten A, Wuyts W . Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax. 2017; 73(6):581-583. PMC: 5969333. DOI: 10.1136/thoraxjnl-2016-209701. View

17.

Kolb M, Richeldi L, Behr J, Maher T, Tang W, Stowasser S . Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2016; 72(4):340-346. PMC: 5520269. DOI: 10.1136/thoraxjnl-2016-208710. View

18.

Bueno M, Lai Y, Romero Y, Brands J, St Croix C, Kamga C . PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis. J Clin Invest. 2015; 125(2):521-38. PMC: 4319413. DOI: 10.1172/JCI74942. View

19.

Putman R, Hatabu H, Araki T, Gudmundsson G, Gao W, Nishino M . Association Between Interstitial Lung Abnormalities and All-Cause Mortality. JAMA. 2016; 315(7):672-81. PMC: 4828973. DOI: 10.1001/jama.2016.0518. View

20.

Herazo-Maya J, Noth I, Duncan S, Kim S, Ma S, Tseng G . Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med. 2013; 5(205):205ra136. PMC: 4175518. DOI: 10.1126/scitranslmed.3005964. View